Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

BLyS antagonists and peptide tolerance induction.

J T Merrill1

  • 1Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City 73104, USA. joan-merrill@omrf.ouhsc.edu

Lupus
|April 6, 2005
PubMed
Summary

Systemic lupus erythematosus (SLE) drug development faces challenges due to disease heterogeneity. Novel biologic agents and tolerance-inducing peptides offer promising, targeted approaches for safer and more effective SLE treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantifying stratosphere-troposphere transport of ozone using balloon-borne ozonesondes, radar windprofilers and trajectory models.

Atmospheric environment (Oxford, England : 1994)·2020
Same author

A double-blind, randomized, placebo-controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus.

The British journal of dermatology·2019
Same author

The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients.

Lupus·2017
Same author

Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to- Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study.

Arthritis care & research·2015
Same author

Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

Annals of the rheumatic diseases·2015
Same author

Genetic association of CD247 (CD3ζ) with SLE in a large-scale multiethnic study.

Genes and immunity·2015

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Background:

  • Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by significant heterogeneity.
  • This heterogeneity complicates drug development and treatment optimization.
  • Novel targeted biologic agents offer potential for more strategic immune modulation in SLE.

Purpose of the Study:

  • To review two novel therapeutic strategies for SLE: BLyS inhibition and peptide-induced tolerance.
  • To evaluate the potential benefits and risks of these targeted approaches.
  • To discuss ongoing clinical development of these SLE treatments.

Main Methods:

  • Review of literature on BLyS inhibition for SLE.
  • Review of literature on peptide-induced tolerance for autoimmune diseases.
  • Analysis of preliminary murine data for tolerance induction in SLE models.

Main Results:

  • BLyS inhibition targets a key protein in SLE pathogenesis but may have broader immune repercussions.
  • Peptide-induced tolerance shows promise for targeted immune modulation with potentially minimal adverse effects.
  • Preliminary murine data suggest limited tolerance induction can impact complex SLE.

Conclusions:

  • Targeted inhibition of BLyS and peptide-induced tolerance represent promising avenues for SLE treatment.
  • Both strategies are advancing to human clinical trials.
  • Further research is needed to fully understand the efficacy and safety profiles of these novel SLE therapies.

Related Experiment Videos